Industry news

• Virus Spread Threatens Pharmaceutical Supplies, Clinical Research

  21 February 2020 Jill Wechsler / BioPharm International

  The continued COVID-19 outbreak has fueled fears of drug shortages, primarily for active pharmaceutical ingredients (APIs) produced in China, including key ingredients in antibiotics, painkillers and diabetes drugs. Although several Chinese manufacturers recently reported they were back in business after the holiday closures, U.S. and European regulatory officials continue to anticipate supply shortages in multiple areas, as are generic drug producers in India, which also obtain APIs from China.

• Personalized Medicine Market Worth $3.92 Trillion by 2026

  21 February 2020 GMP News

  The Global Personalized Medicine market is expected to reach $3.92 trillion by 2026, growing at a CAGR of 12.1% during the forecast period. The efficient and advanced technology and higher prevalence of disease are driving the market growth. However, the higher cost of research and developments is hampering the market.

• Innovation Centre Allows Members to Sample I4.0 Technology Demonstrated in a GMP Environmen

  20 February 2020 GMP News

  A new Innovation Centre has been opened in Dublin, Ireland, by the National Institute for Bioprocessing Research and Training (NIBRT) and Boston Consulting Group (BCG) as part of the Biopharma 4.0 (B4.0) Alliance. The facility will be dedicated to biopharma operations and showcase the latest Industry 4.0 (I4.0) technologies in biopharma manufacturing, bioprocessing, quality control and training. 

• US Biopharmaceutical Industry Creates more than $1.1 Trillion in Economic Output

  20 February 2020 GMP News

  According to the report by TEConomy Partners, the competitive ecosystem of the industry constantly pushing for new medicines is a major driver of US economic growth. The report states that while some states have significantly more employment in the biopharmaceutical industry than others, the industry as a whole supports a sizable number of jobs in every US state, the District of Columbia and Puerto Rico.

• Pharma Industry Calls for a Mutual Recognition Agreement on GMP in EU-UK Future Relationship

  19 February 2020 GMP News

  The pharmaceutical industry in Europe has worked to support the EU27 and UK to reach an agreement that will allow patients to receive medicines and medical technologies without disruption and provide long term co-operation between the EU and the UK in areas such as research, clinical trials, pharmacovigilance and access to talent. European Federation of Pharmaceutical Industries and Associations (EFPIA) and Medicines for Europe and Association of the European Self-Medication Industry (AESGP) has stated that the European pharmaceutical industry has worked to support the EU27 and UK to reach an agreement that will allow patients to receive medicines and medical technologies without disruption.

• Four Novel Coronavirus Vaccines are Currently Being Developed

  19 February 2020 GMP News

  Human trials for one or two of the most promising vaccine candidates could begin in three or four months, WHO chief scientist Soumya Swaminathan said.

• States Rejected an Opioid Settlement Offer by Distributors

  18 February 2020 GMP News

  After years of opioid litigation and a multibillion-dollar settlement offer from the nation’s top drug distributors, nearly two dozen U.S. states have rejected their proposal, The Wall Street Journal reports.

• The Biopharmaceutical Industry is Currently Developing Nearly 600 Pediatric Medicines

  18 February 2020 GMP News

  America’s biopharmaceutical researchers are committed to studying, developing and testing medicines to meet the unique needs of pediatric patients. New treatment options for infants, children and adolescents can be complex and often require different clinical approaches than adult treatment pathways. According to a new report released, there are nearly 600 pediatric medicines currently in development.

• Public Access to Side Effect Reports of Veterinary Drugs in the EU

  17 February 2020 GMP News

  For the first time, EMA is making suspected side effect reports of veterinary medicines authorised in the European Union publicly accessible through the www.adrreports.eu website. The reports come directly from Eudravigilance Veterinary (EVVet), a database for processing pharmacovigilance reports which is used as one of several tools for regulators to monitor the benefit-risk balance of a veterinary medicine once it is authorised.

• Pharma Industry Calls for a Mutual Recognition Agreement on GMP in EU-UK Future Relationship

  17 February 2020 GMP News

  The pharmaceutical industry in Europe has worked to support the EU27 and UK to reach an agreement that will allow patients to receive medicines and medical technologies without disruption and provide long term co-operation between the EU and the UK in areas such as research, clinical trials, pharmacovigilance and access to talent.